Clinical Trials Logo

Carcinoma, Ductal clinical trials

View clinical trials related to Carcinoma, Ductal.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06383533 Recruiting - HER2 Gene Mutation Clinical Trials

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma

NCT ID: NCT06350500 Recruiting - Breast Carcinoma Clinical Trials

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

This clinical trial evaluates a patient navigation program for addressing disparities in breast cancer care. The navigation program is designed to help improve patient knowledge about clinical and supportive care services, navigate to existing services, help manage barriers to care, and enhance patient skills related to management of cancer treatment. Offering a patient navigation program may increase health equity and improve social needs and quality of life over time for newly diagnosed breast cancer patients.

NCT ID: NCT06348264 Recruiting - Clinical trials for Salivary Gland Neoplasm Duct

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Start date: March 30, 2024
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.

NCT ID: NCT06218303 Recruiting - Clinical trials for Ductal Carcinoma in Situ

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Start date: February 7, 2024
Phase: Phase 1
Study type: Interventional

Post-menopausal women with biopsy-proven DCIS will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor alone for about 12 weeks prior to surgery at 12 weeks. The second cohort will receive neoadjuvant therapy with an aromatase inhibitor and MUC1 vaccination (MUC1 peptide + Hiltonol®) pre-operatively at baseline, and weeks 2 and 10, followed by surgery at about 12 weeks. Patients in the vaccine cohort will be offered an optional boost vaccine 6 months after surgery.

NCT ID: NCT06182072 Recruiting - Clinical trials for Pancreatic Ductal Carcinoma

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: September 14, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)

NCT ID: NCT06133647 Recruiting - Clinical trials for Ductal Carcinoma in Situ

Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

Start date: May 4, 2023
Phase:
Study type: Observational

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

NCT ID: NCT06092645 Recruiting - Clinical trials for Bile Duct Adenocarcinoma

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct adenocarcinoma

NCT ID: NCT06075953 Recruiting - Clinical trials for Ductal Carcinoma in Situ

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Start date: February 14, 2024
Phase: Phase 2
Study type: Interventional

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

NCT ID: NCT05932758 Recruiting - Clinical trials for Ductal Carcinoma in Situ

Excisional Vacuum-Assisted Breast Biopsy

Start date: January 17, 2023
Phase: N/A
Study type: Interventional

The goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (VAE) to completely remove the pathology in case of small lesions for Atypical Ductal Hyperplasia (ADH) and low-intermediate grade Ductal Carcinoma in Situ (DCIS).

NCT ID: NCT05900986 Recruiting - Breast Cancer Clinical Trials

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Start date: July 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.